These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8353296)

  • 1. Platelet function and thromboxane synthesis in myeloproliferative disorders.
    Zahavi M; Zahavi J
    Blood; 1993 Aug; 82(4):1377-8. PubMed ID: 8353296
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
    Cieslar P; Matousová O
    Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myeloproliferative disorders and blood platelet function].
    Uchino H
    Rinsho Ketsueki; 1978 Feb; 19(2):187. PubMed ID: 650919
    [No Abstract]   [Full Text] [Related]  

  • 4. [Platelet factor 3 activity in myeloproliferative disorders as evaluation by a new simple method].
    Inceman S; Tangün Y
    Turk Tip Cemiy Mecm; 1970; 36(9):317-20. PubMed ID: 5524541
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 6. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes].
    Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J
    Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850
    [No Abstract]   [Full Text] [Related]  

  • 7. [Arachidonic acids].
    Okuma M
    Rinsho Byori; 1985 Apr; Spec No 62():95-104. PubMed ID: 4032799
    [No Abstract]   [Full Text] [Related]  

  • 8. [Isolation of size-dependent human platelet subpopulations. I. The method for isolation of size-dependent platelet subpopulations by counterflow centrifugal elutriation].
    Saigo K; Ryo R; Nakaya Y; Yamaguchi N; Ryo R; Saigo K; Ueda K
    Rinsho Byori; 1986 Oct; 34(10):1159-62. PubMed ID: 3807001
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator.
    Addonizio VP; Smith JB; Strauss JF; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):91-6. PubMed ID: 7350392
    [No Abstract]   [Full Text] [Related]  

  • 12. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
    Zuk E
    Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloproliferative disorders: a quantitative assessment of platelet ultrastructure.
    Boughton BJ; Jerrome DW; Rychetnik M
    Acta Haematol; 1980; 64(6):319. PubMed ID: 6782797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glycogen synthetase in platelets and in abnormal platelet populations from myeloproliferative syndromes].
    Vainer H; Besson P; Caen J
    Nouv Rev Fr Hematol; 1971; 11(5):769-79. PubMed ID: 4261192
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
    Manoharan A; Gemmell R; Hartwell T
    Am J Hematol; 2006 Sep; 81(9):676-83. PubMed ID: 16795055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)].
    Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S
    Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombocytosis. Diagnostic approach].
    Bauters F
    Rev Prat; 2001 Feb; 51(4):437-42. PubMed ID: 11355610
    [No Abstract]   [Full Text] [Related]  

  • 19. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?
    Zimmermann N; Kurt M; Wenk A; Winter J; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):606-10. PubMed ID: 15784358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of dysplastic platelets by peripheral blood megakaryoblasts in transient myeloproliferative disorder in Down syndrome.
    Chopra A; Kumar R; Kabra M; Anand M
    Platelets; 2008 Mar; 19(2):160-1. PubMed ID: 18297553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.